CTC monitoring in breast cancer detects MRD and supports post-surgery surveillance. Publications 3 November 2025 Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Introduction Early detection of metastasis is important for improving overall survival in breast cancer (BC) patients. Circulating tumor cells (CTCs) play a role in detecting minimal residual disease (MRD). In an ongoing cohort, we evaluated the association between CTC dynamics before and after surgery performed with curative intent. Additionally, we assessed cancer-related worry in post-surgical BC patients. Methods A total of 75 CTC tests were performed on 55 female BC patients, of whom 20 were follow-up cases. In an ongoing IEC-approved clinical cohort, 10 BC patients were enrolled using a quantitative, non-probability purposive sampling method. CTC counts, including clusters, were measured both pre-surgery and 24 hours post-surgery. PD-L1 expression on CTCs was assessed using the CDSCO-approved OncoDiscover platform. Patient-reported outcome measures (PROMs) were evaluated using the Breast-Q Cancer Worry scale, a validated subscale reflecting fear of recurrence and related concerns. Statistical analysis compared PROM scores with CTC patterns, including increase, persistence, or clearance. A paired sample t-test was applied to compare pre- and post-operative PROM scores to evaluate changes in cancer-related worry in relation to CTC counts. Results Among the 75 tests performed in 55 BC patients, 84.5% were CTC-positive, with a mean of 1.43 CTCs per test. In longitudinal monitoring of 10 female BC patients who underwent surgery, six received neoadjuvant chemotherapy (NACT) followed by breast-conserving surgery, while four underwent surgery without prior chemotherapy. Overall, 40% (4/10) showed a reduction in CTC counts, and 20% (2/10) achieved complete CTC clearance after surgery. Patients with increased post-surgery CTC counts reported a significant increase in cancer-related worry. The mean pre-surgery score was 43.9, which increased to 51.8 after surgery. These findings suggest the need for targeted emotional and psychological support in the post-surgical period and highlight the role of CTC monitoring in assessing MRD. Conclusions Monitoring CTCs strengthens their potential as an early indicator of residual disease by providing important clinical insights into tumor activity during the operative phase. Further validation is warranted to support more integrated, patient-centered care approaches aimed at reducing the burden of advanced cancer. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Liquid biopsy may replace invasive procedure to detect cancer Press Release 23 April 2020 Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read the article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dynamic device captures CTCs safely, enabling monitoring and metastatic control. Publications 3 June 2025 Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Background Primary tumors are known to shed circulating tumor cells (CTCs), promoting systemic dissemination and increasing the risk of metastasis to distant organs. Approximately 90% of cancer-related deaths are directly associated with metastasis. Several studies in animal models suggest improved overall survival following reduction in the number of CTCs in circulation. In this study, we demonstrate the capture of CTCs using a continuous blood-flow device incorporating three-dimensional glass substrates (3D GS) conjugated with affinity ligands, including anti-epithelial cell adhesion molecule (EpCAM) antibody and transferrin (Tf), in cancer patients. Methods A bi-spiral, plano-horizontal, optically transparent device fabricated from biocompatible resin with multiple channels for continuous blood flow was designed using a 3D printer. The circulation device comprised 14 loops capable of holding 17.5 mL of blood and containing 680 glass substrates (2 mm diameter) conjugated with anti-EpCAM antibody and transferrin. The system was mechanized for functional circulation using three pumps. Pyrogenicity resulting from blood passage through the device was evaluated in three New Zealand White rabbits according to ISO:10993-11 guidelines for systemic toxicity assessment. Additionally, 27 blood samples from patients with early- and late-stage cancers across nine cancer types, including colorectal, lung, breast, and ovarian cancers, were processed using the OncoDialysis assay. The cohort consisted of 48.15% male and 51.85% female patients. CTCs were captured using five glass substrates from 1.5–5 mL of blood and validated using CK18 and CD45 markers through fluorescence microscopy. Samples were also analyzed using the Drug Controller, India–approved OncoDiscover technology for comparative evaluation. Results No hemolysis was observed as a result of the device. Continuous circulation of up to 5 mL of blood successfully demonstrated CTC capture within the flow system. All rabbits remained healthy during testing, and none exhibited an individual temperature increase of 0.5°C or more compared with controls, indicating no systemic toxicity. The OncoDialysis assay detected CTCs in 48.15% of patients (n = 13/27), yielding a total of 14 CTCs (12 single CTCs and 2 clusters), with a mean CTC distribution of 0.51 per 1–5 mL of blood. The OncoDiscover platform isolated 23 CTCs (18 single CTCs and 5 clusters), with a mean CTC distribution of 0.8. A concurrence rate of 74.07% was observed between the two platforms. In 40.74% of cases (n = 11/27), CTCs were detected by both systems. Conclusions We developed a dynamic in vitro blood circulation device with demonstrated safety in animal studies, capable of selectively capturing circulating tumor cells from patient blood. Reduction of CTC burden may hold significant therapeutic potential in limiting metastatic spread and improving overall survival in epithelial-origin cancers, both in treated and untreated settings. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs and PD-L1 after radiotherapy indicate MRD and possible tumor re-invasion. Publications 25 November 2024 ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. Introduction The presence of circulating tumor cells (CTCs) is a predictor of minimal residual disease (MRD) and treatment outcomes. Abscopal effects of targeted intraoperative radiotherapy have been observed clinically, and the tumor microenvironment may influence these outcomes. Recent reports have shown activation and transit of CTCs following simulated radiotherapy from irradiated regions in vitro. Thus, the cellular extravasation and invasion phenotype cascade of CTCs in irradiated tumor regions could be highly concerning and raises several clinical questions. For the first time, we retrospectively analyzed patients who underwent radiotherapy to observe a clinical correlation between the presence of CTCs and overexpression of the PD-L1 protein in blood circulation as an indicator of minimal residual disease and a potential radiotherapy-associated effect. Methods A cohort of 26 pan-cancer patients (female = 10, male = 16) was analyzed, including cases of colorectal cancer (n = 4), lung cancer (n = 4), endometrial cancer (n = 4), head and neck cancer (n = 4), pancreatic cancer (n = 1), ovarian cancer (n = 1), renal cell carcinoma (n = 4), breast cancer (n = 2), and bone cancer (n = 2). Blood samples were analyzed retrospectively based on clinical and treatment history. Enumeration of CTCs was performed using the immunomagnetic multi-component OncoDiscover platform approved by CDSCO India, mediated by anti-EpCAM antibodies. CTCs were identified based on the presence of CK18+, PD-L1+, DAPI+, and CD45− staining using an automated Zeiss microscope in 1.5 ml of blood samples. Results In the retrospective analysis, a total of 88% (23/26) of patients showed the presence of CTCs in 1.5 ml of blood. Among these patients, 46% (n = 12/26) had undergone radiotherapy at some point during their treatment history. Three patients had received focused radiotherapy for brain metastasis with primary cancers of head and neck (1 case) and endometrium (2 cases). Among patients who underwent radiotherapy, 88% (8/9) were observed to have at least one CTC along with PD-L1 overexpression in at least one CTC. In addition, one patient who underwent radiotherapy showed the presence of a CTC cluster. Conclusions For the first time, we demonstrate the association of CTCs following radiotherapy in irradiated tumor regions. The disseminated CTCs may enhance tumor cell reinvasion through active transit in circulation, supported by a favorable microenvironmental milieu. Further validation with larger clinical cohorts across multiple cancer types is required. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Non-hemolytic adsorbents for toxin isolation, disease tracking & therapy efficacy. Patents 20 October 2025 Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. The present disclosure relates to non-hemolytic adsorbent compositions useful for isolating, enumerating, accounting, and removing the disease-causing toxic constituents in the blood. The said compositions are useful in identifying the disease, disease status, and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease. Methods for isolating, enumerating, accounting, and removing disease-causing toxic constituents in the blood as well as monitoring the disease status and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease are disclosed. Related patent documents US20210106742 WO/2021/074786 CA3154234 IN202044044657 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Cellulose-based transferrin nanocages for CTC enumeration in head & neck cancer. Publications 10 October 2020 Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Herein, we report a hierarchically organized, water-dispersible “nanocage” composed of cellulose nanocrystals (CNCs), magnetically powered by iron oxide (Fe₃O₄) nanoparticles to capture circulating tumor cells (CTCs) from the blood of head and neck cancer (HNC) patients. Capturing CTCs from peripheral blood is extremely challenging due to their low abundance, yet their enumeration is clinically validated in assessing progression-free survival in HNC patients. By engaging multiple hydroxyl groups along the molecular backbone of CNCs, Fe₃O₄ nanoparticles were coordinated onto the CNC scaffold. This structure was further modified through conjugation with the protein transferrin (Tf) to enable targeted capture of CTCs. Owing to the presence of Fe₃O₄ nanoparticles, the nanocages exhibited magnetic properties, allowing CTCs to be captured under the influence of a magnetic field. Tf–CNC-based nanocages were evaluated using blood samples from HNC patients and their CTC capturing efficiency was compared with the clinically relevant Oncoviu platform. The results demonstrated that CNC-derived nanocages efficiently isolated CTCs from patient blood, achieving approximately 85% capture efficiency relative to the standard platform. The capture efficiency was found to vary depending on the concentration of transferrin and Fe₃O₄ nanoparticles immobilized onto the CNC scaffold. We envision that the Tf–CNC platform holds significant potential in liquid biopsy applications for the isolation and enumeration of CTCs, enabling early detection of metastasis in cancer. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Innovations AACR 2026 Publications Publications 22 April 2026 AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Abstract Background While 90% of cancer deaths are associated with metastasis, it is imperative to monitor early-stage cancer patients for the presence of systemic disease to improve overall survival (OS) and progression-free survival (PFS). Despite complete remission, up to 25–50% of colorectal cancer (CRC) stage II–III and early breast cancer cases are known to relapse. Furthermore, the existence of microtumors often remains undetected by radio-imaging tools due to their limited detection thresholds. Following curative-intent therapies, minimal residual cellular disease (MRCD) may persist and is often represented by circulating tumour cells (CTCs). These cells are known for their ability to extravasate and invade distant sites from the primary tumor. They can also evade immune surveillance. Therefore, there is a need to design safer extracorporeal devices for the capture and depletion of CTCs, particularly those overexpressing PD-L1. In this study, we designed an automated device to capture and remove CTCs from whole blood. Methods We developed an automated microprocessor-operated fluidic device, OncoMetastat, equipped with cartridges for blood and reagent tubes, along with a 3D-printed biocompatible spiral channel. The controller unit powers peristaltic pumps that circulate blood through the spiral channel (96 mm diameter × 6 mm height). The system incorporates 2 mm glass beads conjugated with antibodies and transferrin. Additionally, four vibrators provide micro-stirring to enhance CTC capture from 5–10 mL of patient blood samples (n = 54). White blood cell (WBC) count, hemolysis, and protein binding were measured. The beads were scanned for CTCs using markers CK18⁺, DAPI⁺, and CD45⁻ through an automated imaging system and compared with the OncoDiscover CTC enumeration platform approved by CDSCO India. We analyzed true positives, false negatives, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Results Retrospectively, blood samples from 54 pan-cancer patients—including breast, colorectal, prostate, and lung cancer—were analyzed to capture and deplete CTCs. The OncoMetastat platform demonstrated a capture efficiency of over 90% when compared with the OncoDiscover platform. Automated scanning achieved 100% efficiency in CTC imaging compared with manual imaging. Leukocyte adhesion was low with anti-EpCAM and transferrin-coated glass beads (2 ± 1 WBCs per sample, n = 54). WBC counts showed cancer-type-specific trends (mean WBC count/mL: 4.9 × 10⁶ for breast cancer, 3.9 × 10⁶ for rectal cancer, and 3.5 × 10⁶ for prostate cancer), representing a 40% decrease compared with healthy controls (mean 6.9 × 10⁶ WBCs/mL). Clinically insignificant hemolysis (<1%) and minimal protein binding (~1.5%) were observed. Vibration-assisted operation enhanced CTC sequestration, achieving more than 90% cell capture efficiency. The platform demonstrated sensitivity of 94.4%, specificity of 92.9%, PPV of 94.4%, NPV of 92.9%, and overall accuracy of 93.8% for CTC capture. Conclusion This study demonstrates efficient and specific depletion of CTCs using the automated device. The platform shows potential as an extracorporeal system capable of removing CTCs from whole blood, thereby offering a promising strategy to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 profiling across cancers supports monitoring, recurrence detection, and MRD. Publications 3 June 2025 Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Background India presents a diverse genetic pool with varying cancer incidence patterns. Common cancers in the Indian population include head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers. Understanding the distribution of circulating tumor cells (CTCs) across these cancers may help account for cellular minimal residual disease (MRD) and early recurrence in solid tumors. Surgery with curative intent can be further evaluated for residual disease using dual biomarkers such as ctDNA and CTCs. Methods In this retrospective analysis, peripheral blood samples from 5,935 patients across various cancer types—including head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers—were evaluated for the presence of CTCs, with and without PD-L1 overexpression and CTC clusters. CTCs were detected using the OncoDiscover platform approved by CDSCO in 1.5 mL of peripheral blood. The platform utilizes a multifunctional magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibodies. CTCs were confirmed as EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ cells. PD-L1 expression on CTCs was analyzed using linear fluorescence intensity gradients acquired through an automated Zeiss microscope. Additionally, a computational model was developed to evaluate CTC frequency, mean distribution, regression analysis, and normal probability plots to assess predictability across cancer types, age groups, stages, and genders. Results The study included 5,935 patient blood samples, comprising 90.07% baseline and 9.92% follow-up samples. CTC counts ranged from 1 to 10 per 1.5 mL of blood, with a mean value of 1.12. Among the patients, 69.87% (n = 2,854) demonstrated PD-L1 expression on their CTCs, with a mean value of 0.99. The 51–60-year age group exhibited the highest proportion of both total CTCs (19.16%, n = 1,137) and PD-L1–positive CTCs (19.71%, n = 805). Most CTC clusters were identified in breast, colorectal, and endometrial cancers. Pancreatic cancer patients showed the highest mean CTC count (1.4), whereas laryngeal cancer samples had the lowest mean count (0.78). The computational model indicated that the 51–60-year age group had the highest impact on cancer prevalence and mean CTC distribution. The model also demonstrated a strong correlation between blood-based outcomes and normal probability scores. Conclusions Higher CTC counts were strongly associated with advanced disease stages, particularly in cancers prone to hematogenous spread, such as breast, lung, and prostate cancers. Incorporating CTC profiling from baseline into diagnostic and surveillance strategies may enhance personalized cancer management. The presence of CTCs in disease-free survival (DFS) settings suggests potential links to poor therapeutic response, disease progression, and minimal residual disease. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

The POP device effectively removes CTCs from blood to reduce metastatic progression. Publications 15 July 2020 ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival. Background: The presence of circulating tumor cells (CTC) in the vascular system is a tell-tale signature of metastasis in epithelial origin cancers including lung, breast, colorectal and head and neck cancers. Noteworthy, about 90% of cancer deaths are due to the progression of metastasis. Yet, cancer therapy is focussed on inhibiting tumour growth and there is a paucity of options that target metastasis. We demonstrate the POP ‘device’ that removes circulating tumour cells (CTC) from a patient’s blood to reduce the metastatic progression and improve overall survival. Methods: We designed, multi-component glass beads enriched antibody EpCAM conjugate substrates as POP blood fluidic device. We characterized the substrate and accounted for the biocompatibility using whole blood of healthy volunteers. We evaluated, the acute toxicity of substrates using rat (Wistar Albino) whole blood (CPCSEA registration number: 941/PO/Re/S/06/CPCSEA; 31/07/2019) and further studied major histopathological tissues for any toxicity. Finally, we evaluated 06 cancer patients whole blood (1.5 mL) for capturing and for the elimination of CTCs. The captured cells were immuno-stained, and the optimal fluorescence acquisition intensity was critically quantified in accounting CK18 protein overexpression. Results: The multi-component antibody EpCAM based substrate exhibited efficient CTC capture ability with a mean capture efficiency ranging from 40% to 100 % when compared to the OncoDiscover CTC test approved by CDSCO/ drug controller general of India (DCGI). Furthermore, the substrate indicated high biocompatibility primarily exhibited by the absence of haemolysis on whole human blood. Additionally, the preliminary animal experiments in rats showed a 100% survival rate and negligible toxicity to major organs. Conclusions: Removal of circulating tumor cells as a therapeutics is highly implicated in improving the overall survival of epithelial cancer patients. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Single CTC genomics reveals mutations and therapy resistance beyond ctDNA in CRC. Publications 17 September 2024 ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer. Background Plasma ctDNA (circulating tumor DNA) has emerged as a novel biomarker for detecting genomic alterations and for longitudinal monitoring of colorectal cancer (CRC) patients. However, nearly 30% of patients show no mutations detected, potentially missing opportunities for companion therapy. Single circulating tumor cell (sCTC) genomics can provide greater sensitivity in detecting actionable targets. We report comprehensive genomic profiling (CGP) of live sCTCs and paired ctDNA from an advanced CRC patient population. Methods Retrospectively, live sCTCs and CTC clusters were isolated from six patients with stage IV CRC using OncoRADAR technology. Whole genomes of sCTCs were amplified and target-enriched using hybridization capture with OncoIndx, a comprehensive 1080-gene panel, to generate sequencing libraries. These libraries were sequenced on the Illumina NextSeq 2000 platform in paired-end mode with a sequencing depth of 500×. Raw sequence alignment and variant calling were performed using iCare software. Paired ctDNA samples were processed similarly but sequenced at a higher depth of 5500×. Results A total of 22 sCTCs were isolated, including four CTC clusters. The combined mutational landscape revealed 142 clinically relevant mutations, including 65 missense (45.77%), 25 nonsense (17.61%), 16 frameshift (11.27%), 7 indels (4.93%), 10 splice variants (7.04%), and 19 structural variants (13.38%). NRAS was the most frequently mutated gene, occurring in 52% of samples, followed by SMO (47.6%), TAP1 (42.85%), and TP53 (42.5%). In paired ctDNA samples, TP53 (66%), KRAS (50%), and TAP1 (33.33%) were the most frequently mutated genes. At the individual gene level, a 40% concordance was observed between sCTC and ctDNA. The genomic profile of sCTCs was particularly enriched with mutations in proliferative and stemness-maintenance signaling pathways, including NRAS:p.A146T and SMO:p.V392G, suggesting potential therapy evasion mechanisms. CTCs also showed a higher accumulation of immunotherapy resistance signatures, including loss-of-function mutations in STK11 and STAT5B, which were not detected in paired ctDNA samples. Conclusions The genomic profile of sCTCs exhibited enriched mutations in proliferative and stemness-maintenance signaling pathways. Therapy resistance signatures were more prevalent in sCTCs compared to ctDNA and may provide important clinical insights, particularly for patients who cannot provide tissue biopsy samples or show negative ctDNA results. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTCs as biomarkers for relapse detection in rectal cancer with liver metastasis. Publications 29 June 2024 Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report Nirmal Raut, Atul Bharde, Sreeja Jayant, Gaurishankar Aland, Aravindan Vasudevan, Jayant Khandare In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. Despite the challenges in their clinical application, CTCs hold great potential to transform the management of CRC by enabling more personalized and effective treatment approaches. As technology advances, the integration of CTC analysis into routine clinical practice may become a reality, significantly improving outcomes for patients with colorectal cancer. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Marathi news report on early cancer recurrence detection using liquid biopsy. Press Release 29 August 2019 Early Detection of Cancer Recurrence Now Possible in Marathi A feature highlighting innovative liquid biopsy technology that enables early detection of cancer recurrence, with expert insights from Dr. Jayant Khandare of Actorius Innovations and Research in Marathi News Paper This news feature discusses advancements in cancer diagnostics that make early detection of recurrence possible through cutting-edge liquid biopsy techniques. Dr. Jayant Khandare explains how circulating tumor cell–based testing can help monitor disease progression, guide treatment decisions, and improve patient outcomes. The report emphasizes the growing cancer burden and the importance of accessible, minimally invasive diagnostic solutions in India. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe